• Filing Date: 2020-08-04
  • Form Type: 10-Q
  • Description: Quarterly report
v3.20.2
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Income Statement [Abstract]        
NET REVENUE $ 10,038 $ 10,855 $ 24,573 $ 23,745
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,485) (1,174) (3,412) (2,774)
GROSS PROFIT 8,553 9,681 21,161 20,971
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,810 2,834 4,693 5,561
GENERAL AND ADMINISTRATIVE EXPENSES 2,975 3,675 6,156 7,068
SALES AND MARKETING EXPENSES 4,382 6,108 10,054 12,021
DEPRECIATION AND AMORTIZATION 685 654 1,339 1,306
OPERATING EXPENSES 9,852 13,271 22,242 25,956
NET LOSS FROM OPERATIONS (1,299) (3,590) (1,081) (4,985)
INTEREST EXPENSE AND OTHER (1,351) (1,236) (2,643) (2,464)
UNREALIZED FOREIGN CURRENCY GAIN (LOSS), NET 109 49 28 (20)
NET LOSS BEFORE TAXES (2,541) (4,777) (3,696) (7,469)
PROVISION FOR TAXES (5) (261) (48) (332)
NET LOSS $ (2,546) $ (5,038) $ (3,744) $ (7,801)
NET (LOSS) INCOME PER COMMON SHARE — Basic and diluted (in dollars per share) $ (0.51) $ (1.06) $ (0.75) $ (1.65)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING — Basic and diluted (in shares) 5,030,833 4,732,687 5,005,777 4,724,417